Royalty Pharma PLC (RPRX) vs peers
$63.86
Latest weekly close · Market cap $35.6B
RPRX's EV/EBITDA is 28.8x, compared with 12.3x at the middle of 5 peers.
Peer group: Pharmaceuticals. Updated .
| Stock | EV/EBITDA | Own 5-year percentile |
|---|---|---|
| RPRXRoyalty Pharma PLC | 28.8× | n/a, not ranked |
| MRKMerck & Co. | 37.2× | 87 |
| PFEPfizer | 16.8× | 80 |
| VTRSViatris | 12.3× | 84 |
| ZTSZoetis | 10.3× | 9 |
| BMYBristol Myers Squibb | 9.4× | 42 |
| LLYLilly (Eli) | n/a | n/a, not ranked |
| Peer median | 12.3× |
How to read this comparison
Up to eight covered companies in the same industry, largest market value first.
EV/EBITDA divides enterprise value (market value plus debt, minus cash) by EBITDA over the last twelve months. The peer median leaves out RPRX and stocks without a reading.
Each percentile compares a stock with its own weekly readings over the last five years, so 20 means its EV/EBITDA is above 20% of its own past readings. It needs at least 26 weeks of history. It is not a rank against the other stocks in this table.
Different growth rates, margins and financial risks can explain different multiples. Stocks without positive EBITDA have no reading.
RPRX versus the peer median
+134%
- RPRX
- 28.8×
- Peer median
- 12.3×
- Own 5-year median
- 25.8×